Drugs / THERATOPE STn-KLH
last change Aug 2013 re-read 2 minutes ago

THERATOPE STn-KLH

Vaccine

Developed for
breast cancer
Investigated by
Oncothyreon Canada Inc.

Trials 1 · a red edge is where a trial was stopped

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00003638 Jan 1999 → Jan 2007 breast cancer Oncothyreon Canada Inc. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as THERATOPE STn-KLH ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003638
Modality Vaccine “A multicenter, double blinded, randomized phase III trial of the therapeutic cancer vaccine sialy1-Tn (STn) conjugated to keyhole-limpet Hemocyanin (KLH) was completed in an...” PMID 23983823 Aug 2013
Route Subcutaneous “4 subcutaneous vaccinations with THERATOPE STn-KLH vaccine combined with Detox-B Stable Emulsion” NCT00003638